Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan

被引：0
|
作者：
Kosuke Morimoto
Kensuke Moriwaki
Kojiro Shimozuma
Takeo Nakayama
机构：
[1] Kyoto University Graduate School of Medicine,Department of Health Informatics, School of Public Health
[2] Ritsumeikan University,Comprehensive Unit for Health Economic Evidence Review and Decision Support (CHEERS), Research Organization of Science and Technology
[3] Ritsumeikan University,Division of Health Service Research, Department of Biomedical Science, College of Life Sciences
来源：
Journal of Gastroenterology | 2023年 / 58卷
关键词：
Gastric cancer; Cost-effectiveness analysis; Cost–utility analysis; Nivolumab; Partitioned survival analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1188 / 1197
页数：9
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan
    Morimoto, Kosuke
    Moriwaki, Kensuke
    Shimozuma, Kojiro
    Nakayama, Takeo
    [J]. JOURNAL OF GASTROENTEROLOGY, 2023, 58 (12) : 1188 - 1197
  • [2] Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer: a cost-effectiveness analysis
    Zhu, Youwen
    Liu, Kun
    Zhu, Hong
    Wu, Haijun
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
  • [3] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB PLUS CHEMOTHERAPY VS CHEMOTHERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER IN JAPAN
    Morimoto, K.
    Moriwaki, K.
    Shimozuma, K.
    Nakayama, T.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S505 - S505
  • [4] Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma
    Jiang, Yuan
    Li, Yue
    Wang, Larry X. W.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (02) : 499 - 506
  • [5] Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma
    Yuan Jiang
    Yue Li
    Larry X. W. Wang
    [J]. International Journal of Clinical Pharmacy, 2022, 44 : 499 - 506
  • [6] Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis
    Peng-Fei Zhang
    Xuan-Qiong Shi
    Qiu Li
    [J]. Cost Effectiveness and Resource Allocation, 21
  • [7] Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis
    Zhang, Peng-Fei
    Shi, Xuan-Qiong
    Li, Qiu
    [J]. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [8] Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system
    Lang, Wenwang
    Deng, Lian
    Lu, Meijun
    Ouyang, Ming
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (08) : 1027 - 1042
  • [9] First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma: a cost-effectiveness analysis
    Cao, Xueqiong
    Zhang, Mingming
    Li, Na
    Zheng, Bin
    Liu, Maobai
    Song, Xiaobing
    Cai, Hongfu
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [10] COST-EFFECTIVENESS OF PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC ESOPHAGEAL CANCER OR HER2-NEGATIVE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA IN FRANCE
    Aparicio, T.
    Mackosso, C.
    Cagnan, L.
    Bensimon, L.
    Tehard, B.
    Boussahoua, M.
    Zhang, S.
    Qu, T.
    Meng, Y.
    Francois, E.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S109 - S109
12345